Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.
We use cookies to analyze site traffic and to ensure that we give you the best experience on our website. We do not sell data obtained through the use of cookies. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.OkPrivacy policy
